Objective: This scoping review aimed to summarize the published literature on patient involvement in violence risk assessment. Two research questions reviewed the extent of patient involvement and what evidence exists.
Inclusion Criteria: English-language peer-reviewed published articles of any methodology related to violence risk assessment toward others were included. Articles were related to forensic and mental health practice and involve patients directly in the process.
Methods: Five electronic databases were comprehensively searched, as well as the reference lists of included articles. Both authors reviewed articles for inclusion and extracted data from included articles.
Results: Fifteen articles met the inclusion criteria. Articles reported on three approaches to patient engagement in structured violence risk assessment: how patients were involved or experienced the process, using rating scales, and using questions related to patient self-perceived risk. In relation to what evidence existed, four main themes emerged: patient views about risk and their involvement in risk assessment, comparing the predictive accuracy of patient self-rated tools with clinician-rated tools, predictive accuracy of a patient self-rated tool, and comparing risk ratings between patients and clinicians.
Conclusions: There is a dearth of research published about involving patients in their own risk assessment. Patients report both positive and negative experiences of the process. From cohort-type studies, results have shown that patient self-risk assessment can have a similar predictive ability to the clinician ratings related to adverse violence outcomes. Findings from studies can pave the way for future clinical research around the tools that have been developed thus far.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/JFN.0000000000000500 | DOI Listing |
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFBackground: Rater change is inevitable in often lengthy clinical trials in Alzheimer's disease. Other groups have previously assessed the impact of rater change on data variability. Their conclusions varied, possibly due to differing methodologies (e.
View Article and Find Full Text PDFBackground: Pivotal Alzheimer's Disease (AD) trials typically require thousands of participants, resulting in long enrollment timelines and substantial costs. We leverage deep learning predictive models to create prognostic scores (forecasted control outcome) of trial participants and in combination with a linear statistical model to increase statistical power in randomized clinical trials (RCT). This is a straightforward extension of the traditional RCT analysis, allowing for ease of use in any clinical program.
View Article and Find Full Text PDFBackground: Hypertension is a risk factor for cognitive impairment and dementia. Anti-hypertensives (AHT) are commonly used in old age, but their association with cognition and brain pathology is not well understood.
Method: To investigate the relation of AHT with change in cognitive function and postmortem brain pathology, we evaluated 4,207 older persons without known dementia at enrollment and a subset of 1880 participants who died and came to autopsy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!